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Abstract. More than 75% of all Dutch haemophiliacs participated in a mail survey that
included a section on acquired immunodeficiency syndrome (AIDS). Although no cases of
haemophilia-related AIDS had been reported in the Netherlands at the time of our survey,
the threat of AIDS had caused considerable anxiety among Dutch haemophiliacs. This had
led almost a third of the patients to change their therapy schedules. These changes were
mostly not beneficial and possibly counterproductive, since they were not likely to reduce the
risk of human immunodeficiency virus (HIV) infection. Measures that were advised to pre-
vent HIV transmission, such äs the use of condoms, were seldom carried out, even by the
17% seropositive individuals. We conclude that an increase in the informational efforts
towards the patients is called for to avoid ill-advised treatment changes and to enhance
preventive behaviour.
Introduction [2-5]. Patients with haemophilia have been
at high risk of contracting the human immu-
In 1982 it became apparent that the ac- nodeficiency virus (HIV) by infusions of co-
quired immunodeficiency syndrome (AIDS) agulation factor preparations made from hu-
can be transmitted by blood transfusions [1]. man blood. Recently, Steps have been taken
The first case of AIDS in a haemophiliac was to reduce this risk: donors are asked to with-
reported in 1982 in the United States and
since then more than 400 cases among hae- ι
 Grants were received from Het Praeventiefonds
mophiliacs have been reported worldwide (No 28-1099) and De Stichtmg Haemophilia.
74 Rosendaal/Smit/Varekamp/Brocker-Vriends/Suurmeijer/Bnet
draw voluntarily if they belong to one of the
risk groups for AIDS, blood donations are
screened for antibodies to HIV and clotting
factor concentrates are heat-treated. Since
1985, the Central Laboratory of the Dutch
Red Cross also supplies heat-treated cryo-
precipitate. The introduction of these mea-
sures has drastically reduced the risk of in-
fection [6, 7], but unfortunately a number of
haemophiliacs, in some countries up to 80%,
has already been infected [8-12].
The availability of Serologie tests for anti-
HIV antibodies made it also possible to ex-
amine individuals from the risk groups on
request or for medical or research reasons.
The drawbacks of the test in an asymptom-
atic individual have been pointed out in sev-
eral reports. The consequences of seroposi-
tivity are still uncertain [13] so that serious
anxiety and stress may even be the only
result. Stigmatization may evolve, with diffi-
culties regarding occupation, schooling, in-
surance and social contacts [14, 15].
Since no therapy or vaccine against AIDS
is available, the only possible action is pre-
vention. In addition to the measures taken in
the production of blood products, the hae-
mophilia treatment centres in the Nether-
lands and elsewhere advocated a number of
changes in individual therapy. At the same
time the need to maintain adequate treat-
ment was strongly emphasised. Haemophil-
iacs who are HIV carriers may transmit the
virus to their sexual partners [9, 16, 17]. In
order to reduce the risk of HIV transmission
preventive measures were advised. The
treatment centres and the Dutch Haemo-
philia Society cooperated to educate the pa-
tients on these issues and about AIDS in gen-
eral. The treatment centres did this by organ-
ising meetings with their patients äs well äs
informing them individually, while the pa-
tients' Organisation regularly wrote about
AIDS in its magazine and edited a brochure
about AIDS [18].
The aim of our survey was to study the
impact of the threat of AIDS on Dutch hae-
mophiliacs. We compared the seropositivity
rate in the Netherlands with other countries,
and studied the attitude of the patients to-
wards the test. Furthermore, we collected
data on changes in therapy made both in
accordance with and in contrast to the ad-
vice given by the haemophilia treatment
centres, in relation with anxiety caused by
AIDS. Finally, we examined compliance with
measures to prevent HIV transmission.
Methods
The data were collected by standardised mail
questionnaires sent to all 1,162 Dutch haemophiliacs
who were registered at one of the treatment centres or
the Dutch Haemophilia Society [19]. The question-
naire covered a broad ränge of topics concerning hae-
mophilia, includmg AIDS. Ciosing date was January
Ist, 1986. Forms from female carriers were mcluded
only when they had symptomatic haemophilia and
had needed replacement therapy in the precedmg
year. Questionnaires that were completed made-
quately were excluded. Data on type and seventy of
haemophilia were supplemented by Information from
the treatment centres.
The haemophilia treatment centres had agreed on
the followmg adaptations in haemophilia therapy to
reduce the risk of HIV infection: reevaluation of the
need of prophylactic Substitution therapy in all pa-
tients and a change to on demand treatment if possi-
ble; postponement of elective surgery until the avail-
abihty of (proven) safe blood products; preferential
use of desmopressm for patients with moderately
severe or mild haemophilia A. The patients had been
strongly advised, however, not to change their treat-
ment regimens themselves To prevent transmission
of HIV to sexual partners or others the patients had
been advised to use condoms m sexual mtercourse, to
postpone havmg a family and not to share tooth-
brushes or shavmg Utensils with other members of the
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household. Patients on home treatment had (agam)
been mstructed to use special waste disposal contam-
ers for used matenals that might be contammated
Parents assistmg in the home treatment of their chil-
dren had been advised to wear gloves when admmis-
termg transfusions.
Seven items with a five-pomt scale were used to
measure the psychological effect of the AIDS threat.
A combmed scale of 'AIDS-related anxiety' was con-
structed by scormg each item 0 to 4 pomts and adding
the scores for each patient With regard to the anti-
HIV lest we asked the patients whether they had been
tested and whether the lest result was known to them
The mdividuals who had not been tested could mdi-
cate whether they wished to be tested in the near
future or not. We asked the patients to estimate the
nsk of a seropositive mdividual to develop AIDS, on
a seven-pomt scale ranging from 'less than 5%' to
'100%' A list of seven items was mcluded where
patients could mdicate any change m treatment be-
cause of AIDS. Information about current treatment
regimens was obtamed in the general medical section
of the questionnaire. A list was mcluded of the mea-
sures that had been advised to prevent HIV transmis-
sion where the patients could mdicate whether they
carned out these measures 'always', 'sometimes' or
'never' We calculated comphance figures for each
measure, for the patients to whom each measure
apphed, by only accepting 'always' äs carrymg out a
measure in an effective way.
Statistical analysis was performed by usmg χ2-
tests with Cramer's V äs an mdicator for the strength
of relationships. Also used were product-moment cor-
relations tests (Pearson's r). Significance was accepted
at the 0.01 level. All results were analysed separately
for severe, moderately severe and mild haemophiha,
to avoid spunous relationships.
Results
Nine hundred and forty-seven (81 %) out
of the 1,162 questionnaires were returned, of
which 12 had to be excluded from further
analysis. The survey population of 935 pa-
tients included 801 patients with haemo-
philia A (86%), 132 with haemophilia B
(14%), while 2 individuals had factor VII
and factor XIII deflciency, respectively. All
combined, 384 (41%) had severe haemo-
philia (less than 1% clottmg activity), 175
(19%) had moderately severe haemophilia
(1-5% clotting activity) and 376 (40%) had
mild haemophilia (more than 5% clotting
activity). Substitution therapy consisted of
cryoprecipitate (38%), Dutch factor VIII
concentrate (18%), Dutch prothrombin
complex concentrate (9%) and imported
concentrates (3%), while 25% of the patients
indicated not to receive Substitution therapy
regularly and 6 % did not know the name of
the product used. Six percent of the 484
patients with moderately severe or mild hae-
mophilia A had received treatment with des-
mopressin (either exclusively or in combina-
tion with plasma products) in the year pre-
ceding our survey, while almost a third of
them had received transfusions with plasma
products during this period.
AIDS-related anxiety was significantly
higher among patients with severe haemo-
philia than among those with moderately
severe or mild haemophilia, but anxiety was
frequently mentioned by these patients, too
(table I). Sixty-five percent of all 935 pa-
tients mentioned preoccupation with AIDS,
44 % a sense of lost future perspective, 31 %
feelings of depression, 21 % feelings of tense-
ness, while 12 % reported insomnia and 11 %
hypochondria. Social repercussions, i.e. be-
ing avoided, were mentioned only rarely.
Two hundred and seventeen out of the
nine hundred and thirty-five patients had
been tested for HIV antibodies and knew the
result, while 90 had been tested but had cho-
sen not to be informed about the result. The
Proportion of tested patients was similar for
haemophilia A and haemophilia B. More
than a third of all patients with severe hae-
mophilia had been tested, äs compared to 23
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Table I. AIDS-related anxiety
I think that I have AIDS or Symptoms of AIDS
The future looks grim because of AIDS
It makes me feel depressed
I cannot sleep because of it
I feel tense
AIDS is on my mind
Other people avoid me
Respondents by
severe
(n = 384)
17
55
40
20
33
80
4
severity, %
moderate
(n =175)
7
49
33
11
21
65
3
mild
(n = 376)
7
31
21
5
9
51
2
Anxiety scores by severity: r = 0.27; n = 935; p < 0.001. Indicated are those respondents who answered
'sometimes', 'regularly', Often' or 'always'.
and 11 % for moderately severe and mild
haemophilia, respectively (table II). The
overall seropositivity was 17% (36/217),
with the highest prevalence of HIV anti-
bodies among patients with severe haemo-
philia (21 %). Seropositivity in haemophilia
A and haemophilia B did not differ signifi-
cantly.
Most patients were aware of the limited
prognostic value of the anti-HIV test: only
7% out of 935 patients thought that sero-
positivity carried a 100% risk of developing
AIDS, while almost half of the patients
thought this risk to be less than 15 %. More
than 50% of the 628 patients who had not
been tested indicated that they did not want
to be tested. Many argued that they deliber-
ately chose not to know whether they were
seropositive or negative (35%), while partic-
ularly many of the patients with mild hae-
mophilia indicated that they were sure to be
seronegative (33% of all, 47% ofthose with
mild haemophilia). We found no different
anxiety levels between patients who wanted
to be tested in the near future and those who
did not. The seropositive patients had the
highest anxiety scores (mean score 5.6, n =
36). Surprisingly, the seronegative patients
had an anxiety level that was slightly higher
than that of the untested patients (mean
scores 3.6 and 3.1 for severe haemophilia,
n = 107 and n = 183, respectively), although
this difference was not statistically signifi-
cant.
Seven hundred and twenty-three patients
received treatment regularly and 207 (29%)
of them reported a change in their therapy
schedules because of AIDS, evenly distrib-
uted over severe, moderately severe and
mild haemophilia. Some patients reported
several changes (table III). The majority
(63% of 207 patients) reported ill-advised
changes: waiting longer before treating a
bleeding, using smaller doses (or the combi-
nation of these) or the complete abandon-
ment of all treatment. The seropositive pa-
tients reported äs many changes äs the other
patients. The patients who reported to wait
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Table II. Test of HIV antibodies
Test group
Haemophiha A, severe
Haemophiha B, severe
Haemophiha A, moderate
Haemophiha B, moderate
Haemophiha A, mild
Haemophiha B, mild
All
Tested subjects
114
20
34
7
37
3
217
Seropositive, %
21
20
15
0
5
0
17
Untested
203
45
116
18
297
39
718
subjects
Included among untested subjects are 90 paüents who had been tested, but did not know the result of the
test, included in the lest group 'all' are the 2 persons with factor VII and XIII deficiency
Table III. Changes m therapy because of AIDS
Respondents by seventy, %
severe (n = 376) moderate (n
Stopped prophylaxis1
Postponed elective surgery
Changed to DDAVP
Changed to other blood products
Waited longer before treatment
Used smaller doses2
Stopped all treatment
13
1
-
7
14
7
1
3
4
2
2
20
-
2
= 164) mild (n =183)
_
10
4
2
15
-
2
Patients who received treatment regularly were studied
1
 Proportion of patients on prophylaxis n = 183 and n = 18, for severe and moderate haemophiha, respec-
tively
2
 Proportion of patients on home treatment n = 259 and n = 39, for severe and moderate haemophiha,
respectively
longer had a significantly increased delay
between the onset of a bleeding and the
admmistration of a transfusion (χ2 = 37.9;
5 df; V = 0.24; p < 0.001). For patients with
severe haemophilia on home treatment the
average delay was 3.4 h for those patients
who now waited longer, compared to 1.9 h
for those who did not; for the patients not on
home treatment the correspondmg delays
were 4.9 and 3.1 h, respectively. Some pa-
tients reported a delay of more than 12 h. A
similar trend existed for moderately severe
and mild haemophilia (3.9-5.7 and 5.1-8.1
h, respectively). The patients who had made
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Arxieiy score
Fig. 1. Ill-advised changes in
treatment and AIDS-related anxi-
ety. Anxiety score for cumulative
percentage of patients with severe
haemophilia who made ill-advised
changes in their therapy schedule
(·, n = 66) versus those who did not
make these changes (o, n = 318) (r =
0.25; p < 0.001).
ill-advised changes had significantly higher
anxiety levels than the patients who had not
made these changes (mean scores 5.5 and
3.1, for severe haemophilia, n = 66 and n =
318, respectively) (fig. 1).
In table IV we provide the data on mea-
sures to prevent HIV transmission. The great
majority of the patients who were married or
had a steady relationship did not use con-
doms, even if they were seropositive. None
of the parents assisting their children in
home treatment used gloves; several parents
informed us that they thought the use of
gloves to which they were not accustomed
would increase the risk of needle pricking
accidents. Only a minority of the patients on
home treatment used special Containers for
possibly contaminated waste materials. Al-
though the compliance with these measures
was generally low, patients with severe hae-
mophilia and the steropositive individuals
complied significantly more often than the
others. We also found that patients who con-
sidered themselves well-informed about
AIDS were more likely to use condoms (χ2 =
14.3; 4 df; V = 0.17; p < 0.01). The com-
pliance with measures to prevent HIV trans-
mission was slightly higher among patients
with more AIDS-related anxiety (controlling
both for severity of haemophilia and the
result of the test on HIV antibodies, use of
condoms: r = 0.10, n = 505, p < 0.05; post-
ponement of pregnancies: r = 0.33, n = 80,
p < 0.005; use of Containers : r = 0.14, n =
302, p < 0.01).
Discussion
The prevalence of haemophilia can be es-
timated at 7-9/100,000 [20, 21], which im-
plies that we sent questionnaires to 90% of
all Durch haemophiliacs. This figure and the
high response rate make us confident that
our survey presents a reliable overview.
Since only part of all patients had been
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Table IV. Comphance with preventive measures
Measures Respondents by seventy and lest Status, %
Use of condoms1
Postponement of pregnancies-
Use of gloves3
Containers4
severe
16
50
NC
NC
moderate
4
13
NC
NC
mild
4
0
NC
NC
seropositive
32
(50)
0
44
all
9
16
0
39
NC = No classification by seventy of patients on home treatment.
1
 Use of condoms by patients who were marned or had a steady relationship (n = 505) (seventy χ2 = 22.8,
2df, V = 0.21, p < 0 001, seropositivity χ2 = 15 4, l df, V = 0.17, p < 0 001)
2
 Postponement of pregnancies by couples who wanted children, patients marned and younger than 40 years
(n = 80) (seventy. χ2 = 13 l, 2 df; V = 0.40, p < 0.001; seropositivity. this group consisted of only 2 mdividuals)
1
 Use of gloves by parents assisting m home treatment of patients of 12 years and younger (n = 50).
4
 Use of waste Containers for sharp materials by patients on home treatment (n = 302) (seropositivity. not
significant)
tested for HIV antibodies, however, the fig-
ures on seropositivity should be viewed with
some caution. In severe haemophilia a fairly
large sample of one third of the patients had
been tested and the reported seropositivity
rate does not differ much from that reported
by Breederveld et al. [22] who found 19%
seropositive individuals in a prospective
study on 166 patients. Therefore, the num-
ber of seropositive patients in the Nether-
lands is low compared to the data from
France (50%), Germany (53%), the United
Kingdom (39%) and the United States
(80%) [8-11]. It is higher, however, than the
5% seropositivity among Belgian haemo-
philiacs [12]. The low number of seroposi-
tive individuals in the Low Countries can be
explained by the predominant use of plasma
products from local nonpaid donors, and an
early and effective voluntary self-exclusion
of donors belonging to AIDS risk groups
[Van der Poel, unpubl. observations]. This
small use of commercial concentrates may
also explain the absence of a difference in the
seropositivity rate in haemophilia A and B.
Even though at the time of our study no
cases of AIDS and only few cases of AIDS-
related complex had been reported in Dutch
haemophiliacs [4], the threat of AIDS has hit
hard and caused much fear among haemo-
philia patients. The feelings of optimism that
have surrounded the treatment of haemo-
philia during the last decades have made the
impact of this sudden death threat only more
devastating.
A third of the patients chose not to be
tested for HIV antibodies. In the Nether-
lands, public health authorities have pointed
out the drawbacks of the test [23], which evi-
dently has had its influence on the popula-
tion of haemophiliacs. We feel that consider-
ations of public health or the protection of
health care workers do not justify screening
these patients for HIV antibodies, since the
risk of nosocomial HIV transmission is ex-
tremely low [14, 17, 24-26]. One of the rea-
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sons an individual may have for choosing to
be tested is the hope for a negative and thus
reassuring result. In patients with a low risk
of seropositivity, e.g. those with mild hae-
mophilia, one might offer the lest for reasons
of reassurance. It is obvious that patients
need guidance and Information when the
test result is positive; however, our results
indicate that this is also necessary for pa-
tients proven to be seronegative, since, sur-
prisingly, their anxiety scores were not lower
than the scores of patients who had not been
tested.
Fear of AIDS has led to changes in ther-
apy schedules that are mostly not beneficial
and might also be considered counterpro-
ductive: use of smaller doses or waiting lon-
ger before treating a bleeding could well lead
to an increase in the number of transfusions
required. In contrast to the advice of the
treatment centres to use desmopressin when
appropriate, only very few of the patients
had been treated with it. Even though new
HIV infections from plasma products seem
very unlikely, the risk of virus transmission
by using human blood will remain. There-
fore, we feel that a more widespread use of
desmopressin is desirable.
The compliance with the advice for pre-
ventive measures is low, in spite of the Infor-
mation supplied by the haemophilia treat-
ment centres and the Dutch Haemophilia
Society. This finding has also been reported
in two recent reports from the Netherlands
and elsewhere [17, 27]. Presently, efforts
should be aimed at the prevention of HIV
transmission by infected haemophiliacs to
their sexual partners and others. It is of vital
importance that all haemophiliacs are in-
structed about the risk of HIV transmission
and about the appropriate preventive mea-
sures. Only those known to be seronegative
may adopt a more liberal attitude towards
these measures. The scarce use of condoms
in a group that is clearly at risk of transmit-
ting the virus, and that has received ample
information about preventive behaviour jus-
tifies concern about the success of attempts
to educate the heterosexual population at
large about AIDS prevention.
Patients with moderately severe and mild
haemophilia showed considerable anxiety
and made just äs many changes in their ther-
apy schedules äs patients with severe haemo-
philia, although their risk of infection is
much smaller. Since most of these patients
do not visit their treatment centre äs often äs
patients with severe haemophilia, it will be
difficult to reach them with information
about AIDS other than through the populär
press.
Future policy should be aimed at main-
taining a high Standard of treatment for hae-
mophiliacs and prevention of further spread
of HIV infection. The possible danger and
uselessness of ill-advised changes in treat-
ment and the need of practising safe sex will
have to be emphasised again. We feel that
the national patients' organisations and the
World Federation of Hemophilia will be able
to play an important role in this, but the
treatment centres will have to make addi-
tional efforts to reach the nonmembers. Se-
ropositive children entering adolescence de-
serve special attention. The further spread of
AIDS among the population at large, the
recent reports of an increasing risk of devel-
oping AIDS when seropositive and the great
interest for AIDS in the press may well cause
more anxiety among haemophiliacs. The
only way to respond to this and to achieve
the aforementioned goals is a further in-
crease in information about AIDS towards
haemophiliacs.
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